Hepatocellular Carcinoma and Hepatitis B Virus

ABSTRACT

Chronic hepatitis B is the most common cause of hepatocellular carcinoma (HCC) in Asia. Integration of hepatitis B virus (HBV) genome is likely an early event of carcinogenesis. The integrated HBV genome may activate neighboring cellular genes directly to offer a selective growth advantage to the liver cells. Production of hepatitis B X protein can act as a transactivator on various cellular genes for tumor development. Hepatic inflammation and cirrhosis also favors the process of carcinogenesis. Various viral factors associated with hepatocellular carcinoma development include HBV genotype, basal core promoter mutations, and high viral load. Polymorphisms at the androgen receptor-regulating genes and cytokine genes are possible host factors associated with HCC. This review article summarizes the pathogenesis of HBV-related carcinogenesis and the viral and host factors that may increase the risk of HCC development.

Hepatitis B virus - hepatocellular carcinoma - gene - mutation - DNA

REFERENCES

• 1 Beasley R P, Lin C C, Hwang L Y et al.. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan.  Lancet. 1981;  2 1129-1132
• 2 Hwang S J, Tong M J, Lai P P et al.. Evaluation of hepatitis B and C viral markers: clinical significance in Asian and Caucasian patients with hepatocellular carcinoma in the United States of America.  J Gastroenterol Hepatol. 1996;  11 949-954
• 3 Chan H LY, Hui A Y, Wong M L et al.. Genotype C hepatitis B virus infection is associated with increased risk of hepatocellular carcinoma.  Gut. 2004;  53 1494-1498
• 4 McMahon B J, Holck P, Bulkow L et al.. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus.  Ann Intern Med. 2001;  135 759-768
• 5 Liaw Y F, Tai D I, Chu C M et al.. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis: a prospective study.  Gastroenterology. 1986;  90 263-267
• 6 Sherman M, Peltekian K M, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population.  Hepatology. 1995;  22 432-438
• 7 Liaw Y F, Chu C M, Lin D Y et al.. Age-specific prevalence and significance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in Taiwan: a comparison among asymptomatic carriers, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.  J Med Virol. 1984;  13 385-391
• 8 Lindh M, Andersson A S, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus-large-scale analysis using a new genotyping method.  J Infect Dis. 1997;  175 1285-1293
• 9 Chang M H, Chen C J, Lai M S et al.. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children.  N Engl J Med. 1997;  336 1855-1859
• 10 McMahon B J, Bulkow L, Harpster A et al.. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study.  Hepatology. 2000;  32 842-846
• 11 Yuen M F, Cheng C C, Lauder I J et al.. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience.  Hepatology. 2000;  31 330-335
• 12 Gust I D. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia.  Gut. 1996;  38(suppl 2) S18-S23
• 13 Brechot C. Hepatitis B virus (HBV) and hepatocellular carcinoma. HBV DNA status and its implications.  J Hepatol. 1987;  4 269-279
• 14 Yamamoto T, Kajino K, Kudo M et al.. Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA.  Hepatology. 1999;  29 1446-1452
• 15 Brechot C, Hadchouel J, Scotto M et al.. State of hepatitis B virus DNA in hepatocytes of patients with HBsAg positive and HBeAg negative liver diseases.  Proc Natl Acad Sci USA. 1981;  78 3906-3910
• 16 Kam W, Rall L B, Smuckler E A et al.. Hepatitis B viral DNA in liver and serum of asymptomatic carriers.  Proc Natl Acad Sci USA. 1982;  79 7522-7526
• 17 Shafritz D A, Shouval D, Sherman H et al.. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma.  N Engl J Med. 1981;  305 1067-1073
• 18 Yasui H, Hino O, Ohtake K et al.. Clonal growth of hepatitis B virus integrated hepatocytes in cirrhotic liver nodules.  Cancer Res. 1992;  52 6810-6814
• 19 Lugassy C, Bernuau J, Thiers V et al.. Sequences of hepatitis B virus DNA in the serum and liver patients wit acute benign and fulminant hepatitis.  J Infect Dis. 1987;  155 64-71
• 20 Murakami Y, Minami M, Daimon Y, Okanoue T. Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen.  J Med Virol. 2004;  72 203-214
• 21 Pollicino T, Squadrito G, Cerenzia G et al.. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection.  Gastroenterology. 2004;  126 102-110
• 22 Slagle B L, Zhou Y Z, Butel J S. Hepatitis B virus integration event in human chromosome 17p near the p53 gene identifies the region of the chromosome commonly deleted in virus-positive hepatocellular carcinoma.  Cancer Res. 1991;  51 49-54
• 23 Buetow K H, Sheffield V C, Zhu M et al.. Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas.  Proc Natl Acad Sci USA. 1992;  89 9622-9626
• 24 Aguilar F, Harris C C, Sun T et al.. Geographic variation of p53 mutational profile in nonmalignant human liver.  Science. 1994;  264 1317-1319
• 25 Fujimoto Y, Hamptom L L, Wirth P J et al.. Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China.  Cancer Res. 1994;  54 281-285
• 26 Murakami Y, Hayashi K, Hirohashi S, Sekya T. Aberrations of tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinoma.  Cancer Res. 1991;  51 5520-5525
• 27 Nishida N, Fukuda Y, Kokuryu H et al.. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma.  Cancer Res. 1993;  53 368-372
• 28 Pineau P, Marchio A, Mattei M G et al.. Extensive analysis of duplicated-inverted hepatitis B virus integrations in human hepatocellular carcinoma.  J Gen Virol. 1998;  79 591-600
• 29 Minami M, Daimon Y, Mori K et al.. Hepatitis B virus-related insertional mutagenesis in chronic hepatitis B patients as an early drastic genetic change leading to hepatocarcinogenesis.  Oncogene. 2005;  24 4340-4348
• 30 Tamori A, Yamanishi Y, Kawashima S et al.. Alteration of gene expression in human hepatocellular carcinoma with integrated hepatitis B virus DNA.  Clin Cancer Res. 2005;  11 5821-5826
• 31 Wang J, Chenivesse X, Henglein B, Brechot C. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma.  Nature. 1990;  343 555-557
• 32 Dejean A, Bougueleret L, Grzeschik K H, Tiollais P. Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma.  Nature. 1986;  322 70-72
• 33 Murakami Y, Saigo K, Takashima H et al.. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas.  Gut. 2005;  54 1162-1168
• 34 Horikawa I, Barrett J C. Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms.  Carcinogenesis. 2003;  24 1167-1176
• 35 Kim J H, You K R, Kim I H et al.. Over-expression of the ribosomal protein 1.36a gene is associated with cellular proliferation in hepatocellular carcinoma.  Hepatology. 2004;  39 129-138
• 36 Poussin K, Dienes H, Sirma H et al.. Expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas.  Int J Cancer. 1999;  80 497-505
• 37 Tu H, Bonura C, Giannini C et al.. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues.  Cancer Res. 2001;  61 7803-7810
• 38 Wang Y, Lau S H, Sham J S et al.. Characterization of HBV integrants in 14 hepatocellular carcinoma: association of truncated X gene and hepatocellular carcinogenesis.  Oncogene. 2004;  23 142-148
• 39 Benn J, Schneider R J. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade.  Proc Natl Acad Sci USA. 1994;  91 10350-10354
• 40 Benn J, Su F, Doria M, Schneider R J. Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal0-regulated and c-Jun N-terminal mitogen-activated protein kinases.  J Virol. 1996;  70 4978-4985
• 41 Lee Y H, Yun Y. HBx protein of hepatitis B virus activates Jak1-STAT signaling.  J Biol Chem. 1998;  273 25510-25515
• 42 Lee Y I, Kang-Park S, Do S I, Lee Y I. The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade.  J Biol Chem. 2001;  276 16969-16977
• 43 Yen T S. Hepadnaviral X protein: review of recent progress.  J Biomed Sci. 1996;  3 20-30
• 44 Lara-Pezzi E, Majano P L, Gomez-Gonzalo M et al.. The hepatitis B virus X protein up-regulates tumor necrosis factor alpha gene expression in hepatocytes.  Hepatology. 1998;  28 1013-1021
• 45 Yoo Y D, Ueda H, Park K et al.. Regulation of transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X transactivator.  J Clin Invest. 1996;  97 388-395
• 46 Elmore L W, Hancock A R, Chang S F et al.. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis.  Proc Natl Acad Sci USA. 1997;  94 14707-14712
• 47 Takada S, Kaneniwa N, Tsuchida N, Koide K. Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells.  Oncogene. 1997;  15 1895-1901
• 48 Terradillos O, de La Coste A, Pollicino T et al.. The hepatitis B virus X protein abrogates Bcl-2-mediated protection against Fas apoptosis in the liver.  Oncogene. 2002;  21 377-386
• 49 Chami M, Ferrari D, Nicotera P et al.. Caspase-dependent alterations of Ca2+ signaling in the induction of apoptosis by hepatitis B virus X protein.  J Biol Chem. 2003;  278 31745-31755
• 50 Lee T H, Elledge S J, Butel J S. Hepatitis B virus X protein interacts with a probable cellular DNA repair protein.  J Virol. 1995;  69 1107-1114
• 51 Groisman I J, Koshy R, Henkler F et al.. Downregulation of DNA excision repair by the hepatitis B virus-x protein occurs in p53-proficient and p53-deficient cells.  Carcinogenesis. 1999;  20 479-483
• 52 Sirma H, Weil R, Rosmorduc O et al.. Cytosol is the prime compartment of hepatitis B virus where it colocalizes with the proteasome.  Oncogene. 1998;  16 2051-2063
• 53 Schluter V, Meyer M, Hofschneider P H et al.. Integrated hepatitis B virus X and 3′ truncated preS/S sequences derived from human hepatomas encode functionally active transactivators.  Oncogene. 1994;  9 3335-3344
• 54 Luber B, Arnold N, Sturzl M et al.. Hepatoma-derived integrated HBV DNA causes multi-stage transformation in vitro.  Oncogene. 1996;  12 1597-1608
• 55 Soussan P, Garreua F, Zylberberg H et al.. In vivo expression of a new hepatitis B virus protein encoded by a spliced RNA.  J Clin Invest. 2000;  105 55-60
• 56 De Franchis R, Meucci G, Vecchi M et al.. The natural history of asymptomatic hepatitis B surface antigen carriers.  Ann Intern Med. 1993;  118 191-194
• 57 Villeneuve J P, Desrochers M, Infante Rivard C et al.. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal.  Gastroenterology. 1994;  106 1000-1005
• 58 Liaw Y F, Tai D, Chu C M et al.. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis: a prospective study.  Gastroenterology. 1986;  90 263-267
• 59 Ikeda K, Saitoh S, Suzuki Y et al.. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients.  J Hepatol. 1998;  28 930-938
• 60 Fattovich G, Giustina G, Christensen E et al.. Influence of hepatitis B delta virus infection on morbidity and mortality in compensated cirrhosis type B.  Gut. 2000;  46 420-426
• 61 Tsai J F, Jeng J E, Ho M S et al.. Effect of hepatitis C and B virus infection on risk of carcinoma: a prospective study.  Br J Cancer. 1997;  76 968-974
• 62 Norder H, Courouce A M, Magnius L O. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes.  Virology. 1994;  198 489-503
• 63 Stuyver L, De Gendt S, Van Geyt C et al.. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness.  J Gen Virol. 2000;  81 67-74
• 64 Arauz-Ruiz P, Norder H, Robertson B H, Magnius L O. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America.  J Gen Virol. 2002;  83 2059-2073
• 65 Chu C J, Hussain M, Lok A SF. Hepatitis B virus genotype is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C.  Gastroenterology. 2002;  122 1756-1762
• 66 Chan H LY, Wong M L, Hui A Y et al.. Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients.  J Clin Microbiol. 2003;  41 1277-1279
• 67 Sumi H, Yokosuka O, Seki N et al.. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease.  Hepatology. 2003;  37 19-26
• 68 Chan H LY, Tsang S WC, Liew C T et al.. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection.  Am J Gastroenterol. 2002;  97 406-412
• 69 Kao J H, Chen P J, Lai M Y et al.. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B.  Gastroenterology. 2000;  118 554-559
• 70 Fujie H, Moriya K, Shintani Y, Yotsuyanagi H. Hepatitis B virus genotypes and hepatocellular carcinoma in Japan.  Gastroenterology. 2001;  120 1564-1565
• 71 Yu M W, Yeh S H, Chen P J et al.. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men.  J Natl Cancer Inst. 2005;  97 265-272
• 72 Kao J H, Chen P J, Lai M Y, Chen D S. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers.  Gastroenterology. 2003;  124 327-334
• 73 Yuen M F, Sablon E, Yuan H J et al.. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma.  Hepatology. 2003;  37 562-567
• 74 Sugauchi F, Kumada H, Acharya S et al.. Epidemiology and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A.  J Gen Virol. 2004;  85 811-820
• 75 Tanaka Y, Hasegawa I, Kato T et al.. A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D.  Hepatology. 2004;  40 747-755
• 76 Sugauchi F, Orito E, Ichida T et al.. Epidemiology and virological characteristics of hepatitis B virus genotype B having the recombination with genotype C.  Gastroenterology. 2003;  124 925-932
• 77 Kobayashi M, Suzuki F, Akuta N et al.. Virological differences between patients infected with subtypes Ba and Bj of hepatitis B virus genotype B.  J Gastroenterol Hepatol. 2005;  20 570-576
• 78 Chan H LY, Tsui S KW, Tse C H et al.. Epidemiological and virological characteristics of two subgroups of genotype C hepatitis C virus.  J Infect Dis. 2005;  191 2022-2032
• 79 Baptista M, Kramvis A, Kew M C. High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers.  Hepatology. 1999;  29 946-953
• 80 Kuang S Y, Jackson P E, Wang J B et al.. Specific mutations of hepatitis B virus in plasma predict liver cancer development.  Proc Natl Acad Sci USA. 2004;  101 3575-3580
• 81 Buckwold V E, Xu Z, Chen M et al.. Effects of a naturally occurring mutation in the hepatitis virus basal core promoter on precore gene expression and viral replication.  J Virol. 1996;  70 5845-5851
• 82 Scaglioni P P, Melegari M, Wands J R. Biological properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame.  Virology. 1997;  233 374-381
• 83 Chan H LY, Leung N WY, Hussain M et al.. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong.  Hepatology. 2000;  31 763-768
• 84 Sung J JY, Chan H LY, Wong M L et al.. Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients.  J Viral Hepat. 2002;  9 229-234
• 85 Iavarone M, Trabut J B, Delpuech O et al.. Characterisation of hepatitis B virus X protein mutants in tumor and non-tumor liver cells using laser capture microdissection.  J Hepatol. 2003;  39 253-261
• 86 Chan H LY, Hussain M, Lok A SF. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during Hepatitis B e antigen seroconversion.  Hepatology. 1999;  29 976-984
• 87 Lin X, Qian G S, Lu P X, Wen Y M. Full-length genomic analysis of hepatitis B virus isolates in a patient progressing from hepatitis to hepatocellular carcinoma.  J Med Virol. 2001;  64 299-304
• 88 Song B C, Kim H, Kim S H et al.. Comparison of full length sequences of hepatitis B virus isolates in hepatocellular carcinoma patients and asymptomatic carriers in Korea.  J Med Virol. 2005;  75 13-19
• 89 Sung J JY, Tsui S KW, Tse C H et al.. Viral genomic marker associated with the development of hepatocellular carcinoma: a complete genomic sequence of hepatitis B virus.  Gastroenterology. 2005;  128 A743
• 90 Yang H I, Lu S N, Liaw Y F et al.. Hepatitis B e antigen and the risk of hepatocellular carcinoma.  N Engl J Med. 2002;  347 168-174
• 91 Hsu Y S, Chien R N, Yeh C T et al.. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.  Hepatology. 2002;  35 1522-1527
• 92 Di Marco V, Iacono O L, Camma C et al.. The long-term course of chronic hepatitis B.  Hepatology. 1999;  30 257-264
• 93 McMahon B J, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus.  Ann Intern Med. 2001;  135 759-768
• 94 Chan H LY, Wong M L, Hui A Y et al.. The value of hepatitis B virus DNA quantitation to predict hepatitis B e antigen reversion in chronic hepatitis B.  J Clin Microbiol. 2003;  41 4793-4795
• 95 Manesis E K, Papatheodoridis G V, Hadziyannis S J. Serum HBV-DNA levels in inactive hepatitis B virus carriers.  Gastroenterology. 2002;  122 2092-2093
• 96 Martinot-Peignoux M, Boyer N, Colombat M et al.. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers.  J Hepatol. 2002;  36 543-546
• 97 Ohkubo K, Kato Y, Ichikawa T et al.. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma.  Cancer. 2002;  94 2663-2668
• 98 Lin S M, Sheen I S, Chien R N et al.. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.  Hepatology. 1999;  29 971-975
• 99 Van Zonneveld M, Honkoop P, Hansesn B E et al.. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.  Hepatology. 2004;  39 804-810
• 100 Chan H LY, Hui A Y, Wong V WS et al.. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B.  Hepatology. 2005;  41 1357-1364
• 101 Liaw Y F, Sung J J, Chow W C et al.. Lamivudine for patients with chronic hepatitis B and advanced liver disease.  N Engl J Med. 2004;  351 1521-1531
• 102 Yu M W, Chen C J. Elevated serum testosterone levels and risk of hepatocellular carcinoma.  Cancer Res. 1993;  53 790-794
• 103 Tanaka K, Sakai H, Hashizume M, Hirohata T. Serum testosterone: estradiol ration and the development of hepatocellular carcinoma among male cirrhotic patients.  Cancer Res. 2000;  60 5106-5110
• 104 Yu M W, Cheng S W, Lin M W et al.. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma.  J Natl Cancer Inst. 2000;  92 2023-2028
• 105 Yu M W, Yang Y C, Yang S Y et al.. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a case-control study among men.  J Natl Cancer Inst. 2001;  93 1644-1651
• 106 Makridakis N, Reichardt J, Pike M et al.. Genetic control of human androgen metabolism by the CYP17 and SRD5A2 genes.  Am J Hum Genet. 1997;  61(suppl) A257
• 107 Lunn R M, Bell D A, Mohler J L, Taylor J A. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).  Carcinogenesis. 1999;  20 1727-1731
• 108 Lutz M, Knaus P. Integration of the TGF-beta pathway into cellular signaling network.  Cell Signal. 2002;  14 977-988
• 109 Cui W, Fowlis D J, Bryson S et al.. TFGbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice.  Cell. 1996;  86 531-542
• 110 Cambien F, Ricard S, Troesch A et al.. Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de I'infactus du Myocarde (ECTIM) Study.  Hypertension. 1996;  28 881-887
• 111 Kim Y J, Lee H J, Im J P et al.. Association of transforming growth factor-1β1 gene polymorphism with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection.  Exp Mol Med. 2003;  35 196-202
• 112 Migita K, Miyazoe S, Maeda Y et al.. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection: association between TGF-β1 polymorphisms and hepatocellular carcinoma.  J Hepatol. 2005;  42 505-510
• 113 Yamada Y, Okuizumi H, Miyauchi A et al.. Association of transforming growth factor 1-beta genotype with spinal osteophytosis in Japanese women.  Arthritis Rheum. 2000;  43 452-460
• 114 Grainger D J, Heathcote K, Chiano M et al.. Genetic control of the circulating concentration of transforming growth factor type beta1.  Hum Mol Genet. 1999;  8 93-97
• 115 Yamada Y, Miyauchi A, Goto J et al.. Association of a polymorphism of the transforming growth factor beta-1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women.  J Bone Miner Res. 1998;  13 1569-1576
• 116 Tanaka Y, Furuta T, Suzuki S et al.. Impact of interleukin-1β genetic polymorphisms on the development of hepatitis C virus-related hepatocellular carcinoma in Japan.  J Infect Dis. 2003;  187 1822-1825
• 117 Wang Y, Kato N, Hoshida Y et al.. Interleukin-1β gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection.  Hepatology. 2003;  37 65-71
• 118 Shin H D, Park B Y, Kin L H et al.. Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma.  Hum Mol Genet. 2003;  12 901-906
• 119 Heneghan M A, Johnson P J, Clare M, Ho S, Harrison P M, Donaldson P T. Frequency and nature of cytokine gene polymorphisms in hepatocellular carcinoma in Hong Kong Chinese.  Int J Gastrointest Cancer. 2003;  34 19-26
• 120 Werle-Lapostolle B, Bowden S, Locarnini S et al.. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.  Gastroenterology. 2004;  126 1750-1758
• 121 Sung J JY, Wong M L, Bowden S et al.. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy.  Gastroenterology. 2005;  128 1890-1897
• 122 Poon T CW, Hui A Y, Chan H LY et al.. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting-a pilot study.  Clin Chem. 2005;  51 328-335
• 123 Hui A Y, Chan H LY, Wong V WS et al.. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model.  Am J Gastroenterol. 2005;  100 616-623
• 124 Chan H LY, Tsang S WC, Leung N WY et al.. Occult hepatitis B virus (HBV) infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection.  Am J Gastroenterol. 2002;  97 1211-1215
• 125 Huo T I, Wu J C, Lee P C et al.. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis.  Hepatology. 1998;  28 231-236